Finasteride and Flutamide in Pre-surgical Trial in Prostate Cancer.
Status:
COMPLETED
Trial end date:
2017-06-16
Target enrollment:
Participant gender:
Summary
Pre-surgical, window-of-opportunity trials provide a suitable model to assess the activity of preventive interventions in a cost-effective manner using tissue biomarkers as surrogate endpoints. Finasteride has been shown to reduce prostate cancer development in a large phase III trial, and flutamide has a well-known anticancer effect in advanced prostate cancer at the dose of 750 mg/day.
Phase:
PHASE2
Details
Lead Sponsor:
Ente Ospedaliero Ospedali Galliera
Collaborators:
Cliniche Humanitas Gavazzeni European Institute of Oncology Universita degli Studi di Genova Università Politecnica delle Marche University of Arizona